Robert J. Eide - Apr 8, 2025 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role: 10%+ Owner
Signature: /s/ Robert J. Eide
Stock symbol: MTNB
Transactions as of: Apr 8, 2025
Transactions value $: $492,000
Form type: 4/A - Amendment
Date filed: 4/10/2025, 01:59 PM
Date Of Original Report: Mar 7, 2025
Previous filing: Mar 7, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MTNB	Common Stock						1.5K	Apr 8, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MTNB	Series C Convertible Preferred Stock	Purchase	$492K	+492	+100%	$1,000.00^*	984	Apr 8, 2025	Common Stock	840K	$0.59	R. Eide as managing partner for Pembroke	F2, F3, F4, F5
transaction	MTNB	Warrants	Purchase		+1.68M	+100%		3.36M	Apr 8, 2025	Common Stock	1.68M	$0.64	R. Eide as managing partner for Pembroke	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Robert J. Eide is the direct holder of 750 shares of Common Stock, 0.0001 par value per share ("Common Stock") and the indirect holder of 750 shares of Common Stock as the managing member of Isagen LLC.
F2	Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke & Partners ("Pembroke") purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.
F3	Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power of up to 23% of the outstanding Common Stock based on their 984 shares of Preferred Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.
F4	Mr. Eide does not directly own any Preferred Stock or Warrants, however, as the sole manager of Pembroke, Mr. Eide may be deemed to beneficially own securities of the Issuer beneficially owned by Pembroke and share Pembroke's voting power.
F5	N/A